Laveeza Bhatti

Infectious Disease
5901 Green Valley Cir Ste 405
Culver City, CA 90230

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.

TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.

Journal: The Journal of infectious diseases
Published: August 24, 2016

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.

Journal: JAMA
Published: February 24, 2015

The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.

The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.

Journal: HIV medicine
Published: April 14, 2014

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.

Journal: PloS one
Published: October 03, 2013

Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation.

Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation.

Journal: Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)
Published: August 30, 2012

Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.

Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.

Journal: HIV clinical trials
Published: May 18, 2012

Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients.

Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients.

Journal: Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)
Published: May 09, 2012

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

Journal: International journal of clinical practice
Published: October 18, 2011
Showing 1-8 of 8

Last Updated: 09/26/2026